CEO employed since 2014, born 1963. Holdings: 101 648 shares and 575 000 employee options
Göran Forsberg has a PhD in biochemistry, and is an associate professor and the author of over 40 scientific publications. For more than 30 years he has had different positions in research and development, business development and investor relations at pharmaceutical and biotechnology companies, including KabiGen, Pharmacia, Active Biotech and the University of Adelaide, Australia. Forsberg has extensive experience in leading drug development and clinical trials, with a special focus on oncology. Forsberg is a board member of Guard Therapeutics International AB (publ).
COO employed since 2014, born 1963. Holdings: 28 600 shares and 205 000 employee options
Liselotte Larsson has a PhD in biotechnology, and has more than 20 years of experience in various management positions in pharmaceutical and biotechnology companies including BioGaia Fermentation, Novozymes Biopharma and Camurus. Larsson's main fields of expertise are business development, marketing & sales/out licensing, ISO certification, good manufacturing practice (GMP) and overall project management.
VP Clinical Development employed since 2015, born 1961. Holdings: 60 623 shares and 205 000 employee options
Lars Thorsson graduated with a Ph.D. in clinical pharmacology in 1998 and has extensive experience from the pharmaceutical industry, including leading roles in clinical studies and project management in a large number of development phases at AstraZeneca and Novo Nordisk A/S. Thorsson has been responsible for evaluation and documentation of new substances and has the experience of regulatory activities and interactions with health authorities.
VP Research employed since 2015, born 1969. Holdings: 9 215 shares and 205 000 employee options
David Liberg graduated with a Ph.D. in 2001 and has twenty years of research experience within immunology and tumour biology. Liberg has worked within the pharmaceutical industry for the last fiftheen years, with responsibility for early research projects and activities in tumour immunology. He has extensive experience of pre-clinical phase cancer projects. His most recent position was at Active Biotech AB, where he worked as Project Manager Drug Development as well as Head of Cell Biology and Biochemistry. Liberg has also carried out research at Imperial College in the UK and at Lund University, Sweden.
CFO employed since 2017, born 1960. Holdings: 92 000 shares and 205 000 employee options
Bengt Jöndell has a BSc in Business Aministration and a MSc in Chemical engineering. Jöndell has extensive experience in various executive financial functions such as CFO and Chief Executive Officer at BTJ Group AB, Senior Financial Advisor for BoneSupport, CFO/Administrative manager at Inpac, Business Controller at Pharmacia & Upjohn Consumer Healthcare, Pharmacia, Pharmacia Consumer Pharma and Pharmacia Nicorette. Jöndell´s most recent position was CFO for Enzymatica AB.
CMO employed since 2020, born 1964. Holdings: 1 471 shares and 280 000 employee options
Ignacio Garcia-Ribas, is an MD specialized in Medical Oncology with 15 years of experienced in oncology early drug development at global level. His most recently position was in Takeda as Global Clinical Lead across several Phase 1 programs with specific focus in immuno-oncology. Prior to joining Takeda, he was part of Sanofi’s Early Oncology Development Group in the role of Senior Medical Director. Before Sanofi, he was part of the Early Development Unit in Eli Lilly where he contributed to develop several small molecules and antisense oligonucleotides. Dr. Garcia-Ribas obtained his PhD in Medicine at the Richard Dimbleby Department for Cancer Research /ICRF Unit at St. Thomas’ Hospital in London on cancer gene therapy.
Peter Juul Madsen
VP CMC employed since 2020, born 1969. Holdings: 0 shares and 205 000 employee options
Peter Juul Madsen has a M.Sc. in Chemical Engineering from the Technical University of Denmark. He has more than 20 years of experience in managing CMC development including process & analytical development and manufacturing of biological products. Madsen was most recently CMC Project Director at Lundbeck and has extensive experience from outsourcing to contract manufacturing organizations from different CMC project managing positions in e.g. Lundbeck, Genmab and Zealand Pharma.
VP Regulatory Affairs employed since 2020, born 1968. Holdings: 0 shares and 205 000 employee options
Susanne Lagerlund has a Master of Science in Chemical Engineering and has more than 25 years’ experience from the pharmaceutical industry in leading positions at LEO Pharma and AstraZeneca, mainly within Regulatory Affairs. Her most recent role was as Director, Established Portfolio Management at LEO Pharma, where she had responsibility for strategic and tactical management of commercialized portfolios. Lagerlund has also during the last couple of years been responsible within LEO Pharma R&D for the integration of a number of acquired dermatology projects into the commercial portfolio.
VP Biometrics employed since 2021, born 1969.Holdings: 0 shares and 100 000 employee options
Nedjad Losic holds an M.Sc. in Mathematics and a diploma in Management of medical product innovation (SIMI). He has more than 25 years experience of providing biostatistics expertise in clinical drug development, mostly in antibody development and oncology. He has been directly involved in the planning and obtaining market approvals for several biological drugs when at Genmab and Y-mAbs. He has held managerial positions for Ferring, Spadille and Genmab and most recently, as Senior Project Biostatistician in Y-mAbs.